
World Trade Organization members on Tuesday approved measures to make it easier for developing countries to get cheaper generic versions of medicines for communicable diseases like HIV. Changes to the WTO's intellectual property agreement would make permanent a waiver currently in place and allow poor countries without their own pharmaceutical manufacturing capacities to import cheaper copies of patented medicines for humanitarian purposes.
The agreement "confirms once again that members are determined to ensure the WTO's trading system contributes to humanitarian and development goals as they prepare for the Hong Kong ministerial conference," said WTO director-general Pascal Lamy.
Next week's meeting is supposed to set up a conclusion to the current Doha round of trade talks, which aims to cut trade barriers across a wide range of sectors and is supposed to address the needs of developing countries.
"The amendment is designed to match the 2003 waiver as closely as possible," the WTO said in a statement. "In order to achieve this, delegations have been involved in intricate legal discussions aimed at ensuring that the legal meaning and weight, and the hierarchy of provisions, are preserved as exactly as possible."
WTO members have set December 1, 2007, as a deadline to ratify the amendment, the organization said. It would need to be approved by two thirds of the 148 members. The waiver remains in force until then.
"This is a landmark achievement that we hope will help developing countries devastated by HIV/AIDS and other public health crises," said U.S. trade representative Rob Portman.
However, French aid group Doctors Without Borders said the waiver, which the agreement will replace, has failed to prove it can increase access to medicines.
"To date there is no experience using the mechanism—not one patient has benefited from its use—despite the fact that newer medicines, such as second-line AIDS drugs, are priced out of reach of poor patients," the organization said in a statement. "This decision shows that the WTO is ignoring the day-to-day reality of drug production and procurement." (AP)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.